Biocon Limited

Biocon Limited

Biocon Limited has informed the Exchange regarding the resignation of B S R & Co. LLP as the statutory auditors of its material subsidiary, Biocon Biologics Limited, effective August 06, 2026, due to mandatory rotation of the auditors of the holding company.

Biocon Limited

Biocon Limited has informed the Exchange regarding changes in its Directors and Statutory Auditors at the 48th Annual General Meeting (AGM) held on August 06, 2026. The changes include the re-appointment of Mr. Eric Vivek Mazumdar as Director liable to retire by rotation, the appointment of S.R. Batliboi & Associates LLP as Statutory Auditors, and the retirement of Mr. Nicholas Robert Haggar as an Independent Director.

Biocon Limited

Biocon Limited has informed the Exchange regarding Change in Auditors of the company. The company has re-appointed Mr. Eric Vivek Mazumdar as Director liable to retire by rotation, appointed S.R. Batliboi & Associates LLP as the Statutory Auditors, and retired Mr. Nicholas Robert Haggar as an Independent Director.

Biocon Limited

Biocon Limited has informed the Exchange regarding the re-appointment of Mr. Eric Vivek Mazumdar as Non-Executive Director of the company, effective August 06, 2026, and the appointment of S.R. Batliboi & Associates LLP as the Statutory Auditors of the company for a term of 5 years.

Biocon Limited

Biocon Limited held its 48th Annual General Meeting on August 06, 2026, through video conferencing, with 90 members present. The meeting was attended by the Executive Chairperson, Managing Director, and several directors, as well as key managerial personnel and statutory auditors.

Biocon Limited

Biocon Limited has informed the Exchange about the link to the recording of its Q1 FY27 Earnings Call, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Biocon Limited

Biocon Limited has announced its Q1 FY27 earnings, with revenue from operations at ₹4,336 crore, a 10% YoY growth. The company's biosimilars segment saw a 16% YoY growth, driven by the North America market, while the generics segment reported a 21% YoY growth. The company has also announced the EMA approval for its second insulin drug product line in Malaysia, which is expected to support future growth.

Biocon Limited

Biocon Limited has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, as required by SEBI regulations, indicating no deviation from the objects of the Qualified Institutions Placement (QIP) and confirming the utilization of proceeds.

Biocon Limited

Biocon Limited announced its consolidated financial results for the fiscal first quarter ended June 30, 2026, with a total income of Rs 4,391 Cr, up 9% YoY, driven by strong growth in the Biopharma business. The company reported a net profit of Rs 141 Cr, up 355% YoY.

Biocon Limited

Biocon Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of Rs. 638 million and revenue from operations of Rs. 6,245 million.

Biocon Limited

Biocon Limited has announced the commercial launch of Yesafili, a biosimilar to Regeneron's Eylea 2 mg, in the United States. The product was approved by the U.S. FDA in May 2024 and has been granted interchangeable designation, allowing substitution at the pharmacy level in accordance with state laws.

Biocon Limited

Biocon Limited has announced the commercial launch of Yesafili™, a biosimilar to Eylea 2 mg, in the United States. The product was approved by the U.S. FDA and granted interchangeable designation, allowing substitution at the pharmacy level. The launch is expected to benefit approximately 20 million adults in the U.S. with age-related macular degeneration and other serious eye conditions.

Biocon Limited

Biocon Limited has received Notice of Compliance (NOC) approval from Health Canada for its subsidiary's Yesintek (ustekinumab) Autoinjector 45 mg/0.05 mL and 90 mg/mL, strengthening its portfolio of immunology products in Canada.

Biocon Limited

Biocon Limited has informed the Exchange about the schedule of a Board meeting and earnings conference call for analysts and investors to discuss the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026.

Biocon Limited

Mylan Inc. has submitted a disclosure under SEBI Takeover Regulations, as per Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Biocon Limited

Biocon Limited has informed the Exchange regarding Change in Director(s) of the company, specifically the completion of tenure of Independent Director Mr. Bobby Kanubhai Parikh.

Biocon Limited

Biocon Limited has informed the Exchange about the publication of the notice of the 48th Annual General Meeting (AGM) and e-voting information in accordance with SEBI regulations.

Biocon Limited

Biocon Limited has received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee (insulin glargine) at its insulin manufacturing facility in Malaysia.

Biocon Limited

Biocon Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 06, 2026. The company has also sent the Notice of the 48th AGM and Integrated Annual Report for the Financial Year 2025-26 to its members through electronic mode. The report includes information on the company's performance, governance, and sustainability.

Biocon Limited

Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities during the quarter ended June 30, 2026.